Research, Reports & Publications

Sanofi is Recognized with Corporate Responsibility Award

Received at the Pharmaceutical Marketing Excellence Awards 2011 for second consecutive year
Dec 6, 2011 5:00 PM ET

(3BL Media / theCSRfeed) December 6, 2011 - At the Pharmaceutical Marketing Excellence Awards ceremony in London on November 2011, Sanofi was presented with the Corporate Responsibility Award for the second successive year. The Award recognises pharmaceutical companies that have demonstrated an outstanding contribution to society through responsible marketing activities.

Sanofi won the Award for an entry entitled “Human African Trypanosomiasis – Not Neglected by Sanofi”. This refers to its campaign, launched in partnership with the World Health Organisation (WHO) in 2001, to combat Human African Trypanosomiasis (HAT), more commonly referred to as sleeping sickness.   Since the start of the partnership in 2001, over 150,000 patients have been treated for sleeping sickness, a fatal disease if left untreated. The number of patients treated for sleeping sickness has dropped by over 60% since then. The number of reported new cases of the disease fell from 30,000 in 2001 to less than 10,000 in 2009. For the first time, the stage is set for the elimination of sleeping sickness, a prospect that was unthinkable a decade ago. The judging criteria for the Corporate Responsibility Award were the provision of evidence by entrants on: 

  • Evidence of a strong commitment to social responsibility

  • Evidence of a positive impact on the environments, the extended community, or society at large

  • Evidence of how the activity built trust and enhanced industry reputation

  • Clearly identified and effective engagement

  • Sustainability of benefits 

About Human African Trypanosomiasis (HAT): Human African Trypanosomiasis (or sleeping sickness) is a parasitic disease transmitted by the bite of an infected Glossina insect, commonly known as the tsetse fly. The disease affects mostly poor populations living in remote rural areas of Africa. Left untreated, human African trypanosomiasis is usually fatal.   For more information about Sanofi's Access to Medicines program click here. For more information about Corporate Social Responsibility at Sanofi click here.   SANO19346